Skipping Breakfast and Cardiovascular Risk

Several studies have associated skipping breakfast (having little to no breakfast) with increased cardiometabolic risk factors such as obesity, hypertension, dyslipidemia, diabetes and metabolic syndrome. 

Saltearse el desayuno y riesgo cardiovascular

This study examined all the available evidence on the association of skipping breakfast and cardiovascular and all-cause mortality.

It included 4 studies with close to 200,000 adults (mean age ≥40, 48.5% women) with no known cardiovascular disease at recruiting, followed up for mean 17.4 years.

The general analysis suggests that the population which regularly skips breakfast has 21% higher risk of CAD or cardiac death (HR 1.21, CI 95% 1.08 to 1.35; p=0.304) than those that regularly have breakfast.


Read also: Egg Consumption and Mortality Due to Cardiovascular Events.


Even all cause death risk was 32% higher in patients that skip breakfast (HR 1.32, CI 95% 1.17 to 1.48; p=0.339).

Looking closer, we find that the definition of “no breakfast” was heterogeneous between the studies and that the populations were also different, which might have led to misleading outcomes, regardless adjustments. 

Robust data call for further study at long term with consistent definitions of “no breakfast”. 


Read also: Artificially Sweetened Beverages and Alzheimer Risk.


Meanwhile, it seems reasonable (within the primary prevention scope) to recommend our patients have breakfast, which should the most important meal. 

2020-01-16-jcdd-06-00030

Original Title: Skipping Breakfast and the Risk of Cardiovascular Disease and Death: A Systematic Review of Prospective Cohort Studies in Primary Prevention Settings.

Reference: Richard Ofori-Asenso et al. J Cardiovasc Dev Dis 6 (3) 2019 Aug 22.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...